Home
Slovensko sitemapLek sitesask ustext only
 


Company overview
Lek Worldwide
Media Room
Press Releases
Resumes of the Members of the Board of Management
Photos
Advertising
Lek Corporate Identity Manual
Employment Opportunities
Research and Development
Environmental Protection
Business Partners


Prescription Drugs
OTC Products
Active Pharmaceutical Ingredients


Katarina Klemenc Dinjaski
+386 1 580 2243
+386 1 580 2432
Info Lek




Lek | Media Room | Press Releases | Inauguration of Lek's new plant
print this page

Archive
Year 2010
Year 2009
Year 2008
Year 2007
Year 2006
Year 2005
Year 2004
Year 2003
Year 2002
Year 2001
Year 2000
Year 1999
Year 1998

Inauguration of Lek's new plant

18.9.1998 | On September 18, 1998 Lek inaugurated a new plant for production of penicillin products in Prevalje. The plant is expected to contribute significantly to the development of the region, as pointed out by the company's members of management during the panel discussion organized on the occasion. To accompany the important event, Lek in its head office in Ljubljana hosted exhibition of paintings of Stojan Brezoènik, an outstanding Carinthian painter.

The production of pharmaceutical products in Prevalje commenced in 1976, initially within the former Oti¹ki Vrh Textile Industry Plant (TIO). Having outgrown the packaging operations, the newly-founded division focused on production of various products, especially tablets (analgesics). Following the recommendations of the American Food and Drug Administration (FDA) and the WHO, which specify that the production of penicillin be performed separately from other drugs, Lek's production of antibiotics was transferred from Ljubljana to Prevalje a year later. As a result, Lek antibiotic production was the first one in Eastern Europe to fully comply with the mentioned regulations.

The most important product and, consequently, our main investment in Prevalje involves the Amoksiklav® project and a state-of-the-art tablet plant where Lek's number one drug is being produced. The production of Amoksiklav® in Lek started in the year 1987 and the product became very soon one of the leading products of Lek. The major contribution to the quick success of the product was the own production of the main active ingredient, Clavulanic Acid.

To enable a further production growth, a decision to invest CHF 37 million $ in a new plant was adopted in 1994. Already two years later the entire production program was approved by the BSI and Lek was granted the ISO 9001 certificate as the first pharmaceutical plant/company in Europe.

- end -


Lek d.d. All rights reserved.Legal Noticesback to top